PAMU
LAB icon

Pictet Asset Management (UK)’s Standard BioTools LAB Stock Holding History

Pictet Asset Management (UK)’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$83K Buy
+13,490
New +$72.1K ﹤0.01% 1712

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Pictet Asset Management (UK)'s LAB Position: Q2 2021 in Review

Pictet Asset Management (UK) opened a new position in Standard BioTools (LAB) in Q2 2021: 13,490 shares worth $83K. The stake represents ﹤0.01% of the portfolio and ranks #1712 among its holdings.

113 funds tracked by Wall St. Rank hold LAB as of Q2 2021.

  • Pictet Asset Management (UK) held 13,490 shares of Standard BioTools worth $83K as of Q2 2021.
  • Standard BioTools was a new Pictet Asset Management (UK) position in Q2 2021.
  • Standard BioTools made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #1712 holding.
  • 113 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.